Literature DB >> 24240015

The development of an in vitro assay to screen lipid based nanoparticles for siRNA delivery.

Ye Zhang1, Leticia Arrington2, David Boardman2, Jared Davis2, Yan Xu2, Katie DiFelice2, Steve Stirdivant2, Weimin Wang2, Brian Budzik2, Jack Bawiec2, James Deng2, Greg Beutner2, Darla Seifried2, Matthew Stanton2, Marian Gindy2, Anthony Leone2.   

Abstract

In order to rapidly screen and select lead candidates for in vivo evaluation of lipid nanoparticles (LNPs) for systemic small interfering RNA (siRNA) delivery, an in vitro assay amenable to high-throughput screening (HTS) is developed. The strategy is to mimic the in vivo experience of LNPs after systemic administration, such as interactions with serum components, exposure to endosomal pH environments, and interactions with endosomal membrane lipids. It is postulated that the amount of siRNA released from LNPs after going through these treatments can be used as a screening tool to rank order the effectiveness of siRNA delivery by lipid nanoparticles in vivo. LNPs were incubated with 50% serum from different species (i.e. mouse, rat, or rhesus) at 37°C. The resulting samples were then reacted with anionic, endosomal-mimicking lipids at different pHs. The amount of siRNA released from LNPs was determined using spectrophotometry employing the fluorescent indicator SYBR Gold. Our results indicated that the amount of siRNA liberated was highly dependent upon the species of serum used and the pH to which it was exposed. LNPs treated with mouse serum showed higher levels of siRNA release, as did those subjected to endosomal pH (6.0), compared to physiological pH. Most interestingly, a good correlation between the amount of siRNA released and the in vivo efficacy was observed. In conclusion, an in vitro siRNA release assay was developed to screen and rank order LNPs for in vivo evaluation.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Endosome escape; Lipid nanoparticles; Serum stability; siRNA delivery; siRNA release

Mesh:

Substances:

Year:  2013        PMID: 24240015     DOI: 10.1016/j.jconrel.2013.11.006

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  5 in total

1.  Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin.

Authors:  Shanthi Ganesh; Martin L Koser; Wendy A Cyr; Girish R Chopda; Junyan Tao; Xue Shui; Bo Ying; Dongyu Chen; Purva Pandya; Edmond Chipumuro; Zakir Siddiquee; Kevin Craig; Chengjung Lai; Henryk Dudek; Satdarshan P Monga; Weimin Wang; Bob D Brown; Marc T Abrams
Journal:  Mol Cancer Ther       Date:  2016-07-07       Impact factor: 6.261

2.  Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR.

Authors:  Ranganayaki Muralidharan; Anish Babu; Narsireddy Amreddy; Akhil Srivastava; Allshine Chen; Yan Daniel Zhao; Uday B Kompella; Anupama Munshi; Rajagopal Ramesh
Journal:  Mol Cancer Ther       Date:  2017-06-01       Impact factor: 6.261

3.  Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas gene editing.

Authors:  Shuai Liu; Qiang Cheng; Tuo Wei; Xueliang Yu; Lindsay T Johnson; Lukas Farbiak; Daniel J Siegwart
Journal:  Nat Mater       Date:  2021-02-04       Impact factor: 47.656

4.  Zwitterionic Phospholipidation of Cationic Polymers Facilitates Systemic mRNA Delivery to Spleen and Lymph Nodes.

Authors:  Shuai Liu; Xu Wang; Xueliang Yu; Qiang Cheng; Lindsay T Johnson; Sumanta Chatterjee; Di Zhang; Sang M Lee; Yehui Sun; Ting-Chih Lin; John L Liu; Daniel J Siegwart
Journal:  J Am Chem Soc       Date:  2021-12-08       Impact factor: 16.383

5.  Optimization and physicochemical characterization of a cationic lipid-phosphatidylcholine mixed emulsion formulated as a highly efficient vehicle that facilitates adenoviral gene transfer.

Authors:  Soo-Yeon Kim; Sang-Jin Lee; Jin-Ki Kim; Han-Gon Choi; Soo-Jeong Lim
Journal:  Int J Nanomedicine       Date:  2017-10-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.